Latest News by Industry
![Keros Therapeutics, Inc. [KROS] reports annual net loss of $152,992,000.0](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FKROS.png&w=1200&q=75)
Keros Therapeutics, Inc. [KROS] has reported a net loss of $152,992,000.0 for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $151.0 thousand
Based in LEXINGTON, Massachusetts, Keros Therapeutics, Inc. operates in the MANUFACTURING sector.
In the 12 months ended December 31, 2023, the company reported total revenue of $151 million, compared to $0 million in the same period in 2022 and $20.1 billion in 2021.
Operating expenses for the year included research and development costs of $135.3 million, general and administrative expenses of $34.8 million, totaling $170.1 million. This is higher compared to 2022's $114.8 million and 2021's $76.5 million.
The loss from operations for 2023 was $169.9 million, which is an increase from the previous year's loss of $114.8 million and the 2021 loss of $56.4 million.
Other income and expenses amounted to a net income of $17.0 million in 2023, higher than the $10.1 million in 2022.
The company reported a net loss of $153 million in 2023, showing a larger loss compared to the $104.7 million in 2022 and $58.7 million in 2021.
Net loss per share attributable to common stockholders was $5.20 in 2023, higher than the $4.15 in 2022 and $2.52 in 2021 for basic and diluted EPS.
The weighted-average common stock outstanding increased to 29.4 million shares in 2023, from 25.2 million in 2022 and 23.3 million in 2021.
Also Read: